CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 254 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $664,144 | -16.0% | 56,813 | -3.4% | 0.01% | -20.0% |
| Q2 2023 | $790,810 | -22.3% | 58,840 | -4.1% | 0.01% | -23.1% |
| Q1 2023 | $1,017,763 | -60.0% | 61,385 | -55.1% | 0.01% | -23.5% |
| Q4 2022 | $2,542,434 | +134.8% | 136,690 | +62.0% | 0.02% | +13.3% |
| Q3 2022 | $1,083,000 | – | 84,395 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
| GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
| JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
| Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
| Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
| SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
| Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
| Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
| Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |